Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients

Stanford University219 enrolled

Overview

The primary aim of this study is to determine whether we can identify human lung cancer tumor cells in the peripheral blood of lung cancer patients.

The purpose of this study is to determine whether we can identify lung cancer cells circulating in the peripheral blood of lung cancer patients using cell surface markers found on cancer cells such as CD44 and epithelial specific antigen.

Study Type

OBSERVATIONAL

Enrollment

219

Conditions

Lung Cancer

Interventions

phlebotomyPROCEDURE

Standard of care

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria:Inclusion Criteria:Inclusion Criteria (Cases): 1. Advanced stage (IIIB with malignant effusion or IV) histologically or cytologically confirmed NSCLC 2. Patients must be newly diagnosed (untreated) or have evidence of disease progression at the time of sample collection 3. ability to sign informed consent 4. at least 18 years of age Inclusion Criteria (Controls): 1. no known prior or active malignancy 2. ability to sign informed consent 3. at least 18 years of age Exclusion Criteria:1. history of any other cancer other than non-melanoma skin cancer within the last 5 years Exclusion Criteria:1. history of any other cancer other than non-melanoma skin cancer within the last 5 years 2\. pregnant women

Locations (1)

Stanford University School of Medicine

Stanford, California, United States

Outcomes

Primary Outcomes

to determine whether we can identify human lung cancer tumor cells in the peripheral blood of lung cancer patients using cell surface markers found on cancer cells.

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.